CN115337464A - 一种用于牙周组织修复的改性细菌纤维素膜的制备方法 - Google Patents
一种用于牙周组织修复的改性细菌纤维素膜的制备方法 Download PDFInfo
- Publication number
- CN115337464A CN115337464A CN202210973162.8A CN202210973162A CN115337464A CN 115337464 A CN115337464 A CN 115337464A CN 202210973162 A CN202210973162 A CN 202210973162A CN 115337464 A CN115337464 A CN 115337464A
- Authority
- CN
- China
- Prior art keywords
- bacterial cellulose
- cellulose membrane
- solution
- modified bacterial
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002749 Bacterial cellulose Polymers 0.000 title claims abstract description 61
- 239000005016 bacterial cellulose Substances 0.000 title claims abstract description 61
- 239000012528 membrane Substances 0.000 title claims abstract description 53
- 230000003239 periodontal effect Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000017423 tissue regeneration Effects 0.000 title claims abstract description 10
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims abstract description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000008367 deionised water Substances 0.000 claims abstract description 24
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 24
- 238000003756 stirring Methods 0.000 claims abstract description 24
- 238000002791 soaking Methods 0.000 claims abstract description 16
- 238000005406 washing Methods 0.000 claims abstract description 16
- 230000006378 damage Effects 0.000 claims abstract description 9
- 239000004053 dental implant Substances 0.000 claims abstract description 8
- 238000004108 freeze drying Methods 0.000 claims abstract description 8
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 claims abstract description 7
- 229920001661 Chitosan Polymers 0.000 claims abstract description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 7
- 230000035876 healing Effects 0.000 claims abstract description 7
- 230000002093 peripheral effect Effects 0.000 claims abstract description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 4
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 4
- 235000004515 gallic acid Nutrition 0.000 claims description 4
- 229940074391 gallic acid Drugs 0.000 claims description 4
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001149 dopamine hydrochloride Drugs 0.000 claims description 3
- 230000007774 longterm Effects 0.000 abstract description 7
- 230000002439 hemostatic effect Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000003963 antioxidant agent Substances 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 230000007760 free radical scavenging Effects 0.000 abstract description 2
- 210000000601 blood cell Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 201000001245 periodontitis Diseases 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000004402 polyphenol group Chemical group 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 230000003416 augmentation Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000002121 nanofiber Substances 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000000316 bone substitute Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/106—Halogens or compounds thereof, e.g. iodine, chlorite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于牙周组织修复的改性细菌纤维素膜的制备方法,具体为:配置高碘酸钠溶液,取细菌纤维素膜样品浸泡于高碘酸钠溶液中,避光慢速搅拌3h,去离子水反复浸泡至去除多余的高碘酸钠,得到样品A;将羧甲基壳聚糖溶解在去离子水中,随后加入NaOH调节溶液至碱性环境,再加入儿茶酚衍生物,搅拌20min,得到溶液B;将样品A和溶液B混合后,慢速搅拌6h,取出后用去离子水反复洗涤,洗涤干净后冷冻干燥,获得所需炎性破坏后牙种植体周组织愈合的改性细菌纤维素膜。本发明制备的改性细菌纤维素膜其具备了良好的液体吸收能力;具有抗菌、抗炎、止血、抗氧化、清除自由基等多功能;具有良好的力学性能,并且具备长期抗菌能力。
Description
技术领域
本发明属于生物材料技术领域,尤其涉及一种用于牙周组织修复的改性细菌纤维素膜的制备方法。
背景技术
牙周炎是导致成年人牙齿缺失的首要原因,虽然种植修复已日趋广泛地应用于牙周炎患者,但是在重度牙周炎病例中,牙种植体周组织因长期受到炎性破坏而伴有牙槽骨低平、角化龈宽度减少、感染风险加重等表现,导致其种植修复的效果及长期成功率均远低于牙周健康者。足够的软硬组织支持和良好的炎症控制是种植修复长期成功的保障。
细菌纤维素(BC)是由细菌产生的纤维素。它的分子式和聚合结构与植物生产的纤维素相同。半纤维素、果胶和木质素的缺失减少了进一步纯化的工作量。BC具有凝胶状原纤维网络,具有高保水能力、机械强度和生物相容性。由于BC膜具有与生物组织相似的结构和高含水量,因此基于BC材料介导炎性破坏后牙种植体周组织愈合具有潜在的应用前景。多酚类物质具有抗菌、抗炎、止血、抗氧化、清除自由基等多功能。因此,多酚生物材料在应对炎性破坏后牙种植体周组织愈合中能起到关键作用。
目前牙周骨增量方法常采用自体骨移植或骨代用品进行骨诱导,软组织即角化龈增量手术主要有自体结缔组织移植瓣、游离龈移植等。然而,自体骨移植手术和角化龈增量手术需要增加第二术区,骨代用品存在骨诱导能力不足、粘附性能差、免疫排斥反应、力学不匹配、抗炎及免疫调节功能缺乏等缺点。
发明内容
本发明的目的是制备一种用于牙周组织修复的改性细菌纤维素膜,具有止血、抗炎、保水、体内长期稳定的性能,以促软硬组织再生。为此,本发明提供一种用于牙周组织修复的改性细菌纤维素膜的制备方法。
本发明的一种用于牙周组织修复的改性细菌纤维素膜的制备方法,包括以下步骤:
步骤1:配置浓度为0.05M的高碘酸钠溶液,取细菌纤维素膜样品浸泡于高碘酸钠溶液中,避光慢速搅拌3h,去离子水反复浸泡至去除多余的高碘酸钠,得到样品A。
步骤2:将羧甲基壳聚糖溶解在去离子水中,随后加入NaOH调节溶液至碱性环境,NaOH的质量分数为50%,碱性环境为pH=11;再加入儿茶酚衍生物,搅拌20min,得到溶液B。
步骤3:将步骤1得到的样品A和步骤2得到的溶液B混合后,慢速搅拌6h,取出后用去离子水反复洗涤,洗涤干净后冷冻干燥,获得所需炎性破坏后牙种植体周组织愈合的改性细菌纤维素膜。
上述儿茶酚衍生物为多巴胺盐酸盐、没食子酸、表没食子儿茶素没食子酸酯的一种。
本发明的有益技术效果为:
(1)本发明制备的改性细菌纤维素膜,通过高碘酸钠对细菌纤维素膜进行氧化,并引入亲水性多酚基团,得到了具有较大孔隙的细菌纤维素膜。使其具备了良好的液体吸收能力。
(2)本发明制备的具有多酚基团的改性细菌纤维素膜,具有抗菌、抗炎、止血、抗氧化、清除自由基等多功能。除此之外,多酚通过与血液中的亲核试剂相互作用促进血细胞的聚集和粘附。因此该材料表现出较低的血液凝结指数和良好的血细胞粘附能力。
(3)本发明制备的改性细菌纤维素膜,通过进一步引入羧甲基壳聚糖,修复了在氧化过程中破坏纤维网络结构,并部分连接了材料孔隙,使其具有良好的力学性能,并且具备长期抗菌能力。
附图说明
图1为本发明实施例制备的改性细菌纤维素膜的SEM图。
图2为本发明实施例制备的改性细菌纤维素膜的溶胀性能测试图。
图3为本发明实施例制备的改性细菌纤维素膜的降解测试图。
图4为本发明实施例制备的改性细菌纤维素膜的止血性能测试图。
图5为本发明实施例制备的改性细菌纤维素膜的血细胞粘附的SEM图。
具体实施方式
下面结合具体附图和实施例对本发明做进一步详细说明。
本发明的一种用于牙周组织修复的改性细菌纤维素膜的制备方法,包括以下步骤:
步骤1:配置浓度为0.05M的高碘酸钠溶液,取细菌纤维素膜样品浸泡于高碘酸钠溶液中,避光慢速搅拌3h,去离子水反复浸泡至去除多余的高碘酸钠,得到样品A。
步骤2:将羧甲基壳聚糖溶解在去离子水中,随后加入NaOH调节溶液至碱性环境,NaOH的质量分数为50%,碱性环境为pH=11;再加入儿茶酚衍生物,搅拌20min,得到溶液B。
步骤3:将步骤1得到的样品A和步骤2得到的溶液B混合后,慢速搅拌6h,取出后用去离子水反复洗涤,洗涤干净后冷冻干燥,获得所需炎性破坏后牙种植体周组织愈合的改性细菌纤维素膜。
上述儿茶酚衍生物为多巴胺盐酸盐、没食子酸、表没食子儿茶素没食子酸酯的一种。
实施例1
OBC-PDA-CMC的制备:置0.05M的高碘酸钠溶液,取适当大小的BC膜(80*80*3mm)浸泡于高碘酸钠溶液中,避光慢速搅拌3h,去离子水反复浸泡至去除多余的高碘酸钠,得到样品A。将0.5g CMC溶解在50ml去离子水中,再加入0.25g多巴胺和1mL NaOH(0.5g/mL)溶液,搅拌20min后加,得到溶液B。样品A和步骤2得到的溶液B混合后,慢速搅拌6h,取出后用去离子水反复洗涤,洗涤干净后冷冻干燥,得到所述的改性细菌纤维素膜。
实施例2
OBC-PGA-CMC的制备:置0.05M的高碘酸钠溶液,取适当大小的BC膜(80*80*3mm)浸泡于高碘酸钠溶液中,避光慢速搅拌3h,去离子水反复浸泡至去除多余的高碘酸钠,得到样品A。将0.5g CMC溶解在50ml去离子水中,再加入0.25g没食子酸和1mL NaOH(0.5g/mL)溶液,搅拌20min后加,得到溶液B。样品A和步骤2得到的溶液B混合后,慢速搅拌6h,取出后用去离子水反复洗涤,洗涤干净后冷冻干燥,得到所述的改性细菌纤维素膜。
实施例3
OBC-PTA-CMC的制备:置0.05M的高碘酸钠溶液,取适当大小的BC膜(80*80*3mm)浸泡于高碘酸钠溶液中,避光慢速搅拌3h,去离子水反复浸泡至去除多余的高碘酸钠,得到样品A。将0.5g CMC溶解在50ml去离子水中,再加入0.25g单宁酸和1mL NaOH(0.5g/mL)溶液,搅拌20min后加,得到溶液B。样品A和步骤2得到的溶液B混合后,慢速搅拌6h,取出后用去离子水反复洗涤,洗涤干净后冷冻干燥,得到所述的改性细菌纤维素膜。
实施例4
OBC-PEGCG-CMC的制备:置0.05M的高碘酸钠溶液,取适当大小的BC膜(80*80*3mm)浸泡于高碘酸钠溶液中,避光慢速搅拌3h,去离子水反复浸泡至去除多余的高碘酸钠,得到样品A。将0.5g CMC溶解在50ml去离子水中,再加入0.25g表没食子儿茶素没食子酸酯和1mLNaOH(0.5g/mL)溶液,搅拌20min后加,得到溶液B。样品A和步骤2得到的溶液B混合后,慢速搅拌6h,取出后用去离子水反复洗涤,洗涤干净后冷冻干燥,得到所述的改性细菌纤维素膜。
图1为本发明所述的改性细菌纤维素膜的SEM图。从图中可以看出,BC(见图1a)的3D纳米网络在OBC(见图1b)中得到保留,BC被高碘酸钠氧化后,纤维被部分打断,孔隙略微变大。在OBC中引入PDA后,可以观察到OBC-PDA(见图1c)样品纳米纤维直径有所增加,PDA已自发粘附在了OBC的表面。通过观察OBC-CMC-PDA(见图1d)样品,可以看到纳米纤维之间的孔隙部分被CMC所连接。
图2为本发明实施例制备的改性细菌纤维素膜的溶胀性能测试图。从图2a中可以看出,细菌纤维素无论改性与否,吸水溶胀后体积的变化都不明显。从图2b中可以看出,OBC-PDA敷料和OBC-CMC-PDA敷料有较高的溶胀率。这主要归因于两种敷料中含有氨基等亲水基团,这使得OBC-PDA和OBC-CMC-PDA敷料有较好的水合能力,且OBC-PDA和OBC-CMC-PDA敷料段时间的吸水速率较高,在10min左右就可以吸收自身重量数十倍的水分,有助于应用于牙周炎伤口时迅速吸收血液。
图3为本发明实施例制备的改性细菌纤维素膜的降解测试图。从图3a和图3b中可以看出在降解7天内,细菌纤维素膜都没有显示出明显的体积变化和质量损失,表现出了长期稳定性,可以用于牙周炎种植体部位的植入。
图4为本发明实施例制备的改性细菌纤维素膜的止血性能测试图。相对凝血指数越低,表明样品的止血能力越强。OBC样品的先对BCI为34.78±3.96%,OBC-PDA样品的相对BCI为12.98±1.85%,OBC-CMC-PDA样品的相对BCI为12.25±3.12%,BCI均小于100%,说明OBC-PDA、OBC-CMC-PDA敷料均具有一定的促凝血作用。由OBC改性的两组细菌纤维素膜的相对BCI得到下降,凝血性能得到加强。
图5为本发明实施例制备的改性细菌纤维素膜的血细胞粘附的SEM图。在OBC(见图5a)表面仅有少量血细胞粘附,在OBC-PDA(见图5b)表面附着的血细胞有明显增加,而在OBC-CMC-PDA(见图5c)表面观察到大量聚集血细胞。这归因于OBC-CMC-PDA具有带正电荷的氨基,可以通过氢键和静电相互吸引与带负电荷的血细胞发生相互作用,从而吸附血细胞,加速凝血过程。另一方面,OBC-PDA与OBC-CMC-PDA相比,OBC-PDA有更稳定的孔隙结构,一方面使得OBC-PDA敷料具有快速吸收血液中水分的能力另一方面提供了更大的表面积,有利于吸附更多的血细胞,增强止血效果。
本发明首先利用高碘酸钠氧化细菌纤维素产生醛基,之后通过在细菌纤维素3D纳米纤维网络中引入多酚基团以及羧甲基壳聚糖,制备了一种改性细菌纤维素膜。碘酸钠对细菌纤维素膜进行氧化后,打断了密集的纤维,增大了膜的孔隙,使其具备更好的液体吸收能力。引入多酚基团后,该材料具有抗菌、抗炎、止血、抗氧化、清除自由基等多功能。羧甲基壳聚糖的引入部分修复了在氧化过程中被破坏的纤维素网络结构,提高了膜的力学强度。实现了用作炎性破坏后牙种植体周组织愈合的改性细菌纤维素膜的目的,具有止血、抗炎、保水、体内长期稳定的性能,以促软硬组织再生。
Claims (2)
1.一种用于牙周组织修复的改性细菌纤维素膜的制备方法,其特征在于,包括以下步骤:
步骤1:配置浓度为0.05M的高碘酸钠溶液,取细菌纤维素膜样品浸泡于高碘酸钠溶液中,避光慢速搅拌3h,去离子水反复浸泡至去除多余的高碘酸钠,得到样品A;
步骤2:将羧甲基壳聚糖溶解在去离子水中,随后加入NaOH调节溶液至碱性环境,NaOH的质量分数为50%,碱性环境为pH=11;再加入儿茶酚衍生物,搅拌20min,得到溶液B;
步骤3:将步骤1得到的样品A和步骤2得到的溶液B混合后,慢速搅拌6h,取出后用去离子水反复洗涤,洗涤干净后冷冻干燥,获得所需炎性破坏后牙种植体周组织愈合的改性细菌纤维素膜。
2.根据权利要求1所述的一种用于牙周组织修复的改性细菌纤维素膜的制备方法,其特征在于,所述儿茶酚衍生物为多巴胺盐酸盐、没食子酸、表没食子儿茶素没食子酸酯的一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210973162.8A CN115337464B (zh) | 2022-08-15 | 2022-08-15 | 一种用于牙周组织修复的改性细菌纤维素膜的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210973162.8A CN115337464B (zh) | 2022-08-15 | 2022-08-15 | 一种用于牙周组织修复的改性细菌纤维素膜的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115337464A true CN115337464A (zh) | 2022-11-15 |
CN115337464B CN115337464B (zh) | 2023-12-15 |
Family
ID=83951361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210973162.8A Active CN115337464B (zh) | 2022-08-15 | 2022-08-15 | 一种用于牙周组织修复的改性细菌纤维素膜的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115337464B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116510058A (zh) * | 2023-03-28 | 2023-08-01 | 哈尔滨工业大学 | 一种抗菌型细菌纤维素基创伤敷料的制备方法和应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102961777A (zh) * | 2012-12-11 | 2013-03-13 | 北京科技大学 | 改性纳米纤维素多孔复合型高吸渗止血敷料的制备方法 |
CN106084302A (zh) * | 2016-05-31 | 2016-11-09 | 北京科技大学 | 自交联醛化纳米细菌纤维素功能性多孔材料及制备方法 |
CN106178133A (zh) * | 2016-08-16 | 2016-12-07 | 烟台正海生物科技股份有限公司 | 一种可降解的脑膜修复材料及其制备方法 |
CN106822980A (zh) * | 2017-01-21 | 2017-06-13 | 北京科技大学 | 一种塑化纳米细菌纤维素功能敷料及其制备方法 |
CN110156915A (zh) * | 2019-05-27 | 2019-08-23 | 北京科技大学 | 一种儿茶酚/n-甲基丙烯酰化壳聚糖衍生物及其制备方法 |
CN111320770A (zh) * | 2020-04-20 | 2020-06-23 | 张丙起 | 加速创面愈合的烧伤科用生物凝胶及其制备方法 |
CN113802364A (zh) * | 2021-09-01 | 2021-12-17 | 昆明理工大学 | 一种自修复、耐酸碱、抗菌多层膜涂层的制备方法 |
CN113827763A (zh) * | 2020-06-08 | 2021-12-24 | 华东交通大学 | 一种中药成分改性的多功能细菌纤维素基皮肤敷料及其制备方法 |
CN114681657A (zh) * | 2022-04-19 | 2022-07-01 | 南方医科大学 | 具有预防疤痕生成功能的可降解抗氧化胶黏剂及其制备方法和应用 |
-
2022
- 2022-08-15 CN CN202210973162.8A patent/CN115337464B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102961777A (zh) * | 2012-12-11 | 2013-03-13 | 北京科技大学 | 改性纳米纤维素多孔复合型高吸渗止血敷料的制备方法 |
CN106084302A (zh) * | 2016-05-31 | 2016-11-09 | 北京科技大学 | 自交联醛化纳米细菌纤维素功能性多孔材料及制备方法 |
CN106178133A (zh) * | 2016-08-16 | 2016-12-07 | 烟台正海生物科技股份有限公司 | 一种可降解的脑膜修复材料及其制备方法 |
CN106822980A (zh) * | 2017-01-21 | 2017-06-13 | 北京科技大学 | 一种塑化纳米细菌纤维素功能敷料及其制备方法 |
CN110156915A (zh) * | 2019-05-27 | 2019-08-23 | 北京科技大学 | 一种儿茶酚/n-甲基丙烯酰化壳聚糖衍生物及其制备方法 |
CN111320770A (zh) * | 2020-04-20 | 2020-06-23 | 张丙起 | 加速创面愈合的烧伤科用生物凝胶及其制备方法 |
CN113827763A (zh) * | 2020-06-08 | 2021-12-24 | 华东交通大学 | 一种中药成分改性的多功能细菌纤维素基皮肤敷料及其制备方法 |
CN113802364A (zh) * | 2021-09-01 | 2021-12-17 | 昆明理工大学 | 一种自修复、耐酸碱、抗菌多层膜涂层的制备方法 |
CN114681657A (zh) * | 2022-04-19 | 2022-07-01 | 南方医科大学 | 具有预防疤痕生成功能的可降解抗氧化胶黏剂及其制备方法和应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116510058A (zh) * | 2023-03-28 | 2023-08-01 | 哈尔滨工业大学 | 一种抗菌型细菌纤维素基创伤敷料的制备方法和应用 |
CN116510058B (zh) * | 2023-03-28 | 2024-03-15 | 哈尔滨工业大学 | 一种抗菌型细菌纤维素基创伤敷料的制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115337464B (zh) | 2023-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104857569A (zh) | 一种丝素与氧化石墨烯复合支架材料的制备方法 | |
KR20140129234A (ko) | 재흡수성 셀룰로오스 기재의 생체 재료 및 임플란트 | |
CN1214821C (zh) | 异种骨胶原基质制备的新方法 | |
CN111962210B (zh) | 一种聚己内酯/甲基丙烯酰化弹性蛋白纳米纤维复合膜及其制备方法和应用 | |
CN111303452B (zh) | 一种仿生抗菌高粘附的双网络水凝胶及其制备方法和应用 | |
CN1235646C (zh) | 一种多功能生物修复材料的制备方法 | |
CN103301506A (zh) | 一种抗凝血丝素膜及其制备方法 | |
CN115337464B (zh) | 一种用于牙周组织修复的改性细菌纤维素膜的制备方法 | |
CN112807475B (zh) | 一种高透气性可降解的载药皮肤创伤敷料及其制备方法 | |
Bao et al. | Agar/collagen membrane as skin dressing for wounds | |
CN110507842B (zh) | 一种细菌纤维素/透明质酸/ε-聚赖氨酸功能型敷料及其制备方法 | |
CN109731141B (zh) | 一种引导组织修复的复合膜及其制备方法和应用 | |
Ponrasu et al. | Isabgol–silk fibroin 3D composite scaffolds as an effective dermal substitute for cutaneous wound healing in rats | |
CN1526765A (zh) | 复合骨组织工程支架材料及其制备方法 | |
CN113577392A (zh) | 一种复合脱细胞骨膜基质的人工骨膜及其制备方法和应用 | |
CN109966540B (zh) | 一种纳米甲壳素复合海藻酸钙医用敷料的制备方法及应用 | |
WO2007146946A2 (en) | Implantable microbial cellulose materials for hard tissue repair and regeneration | |
CN1157443C (zh) | 柔韧丝素蛋白膜及其制备方法 | |
EP2070557A1 (en) | Implantable microbial cellulose materials for hard tissue repair and regeneration | |
CN107875454B (zh) | 一种用于引导组织再生的胶原复合膜及其制备方法与应用 | |
CN214805987U (zh) | 脱细胞真皮复合敷料 | |
CN115105639B (zh) | 一种用于牙周组织修复的复合膜及其制备方法 | |
CN117339026B (zh) | 用于植入人体牙槽骨中的可吸收支架的制备及应用 | |
CN114984323B (zh) | 一种腹壁缺损修复材料及制备方法 | |
CN115322451A (zh) | 一种纳米羟基磷灰石复合水凝胶及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |